Back to top

vaccines: Archive

Zacks Equity Research

Moderna Stock Jumps After FDA Reverses Course on Flu Shot

MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.

SNYNegative Net Change GSKNegative Net Change MRNANegative Net Change

Zacks Equity Research

Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates

MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and reaffirming 2026 outlook.

MRKNegative Net Change VRTXNegative Net Change MRNANegative Net Change

Zacks Equity Research

Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?

MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.

MRKNegative Net Change MRNANegative Net Change JAZZPositive Net Change CSTLNegative Net Change